- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that its President and CEO Christopher Anzalone, Ph.D., was featured in a Medical Research, Diagnostic Substances & Life Science Tools Report published by The Wall Street Transcript.
Topics covered by Dr. Anzalone include Arrowhead's operational and clinical progress with its RNAi, obesity and regenerative medicine programs, the Company's paradigm shifting technologies under development, strategic growth initiatives and key catalysts for which investors and industry experts should watch for in the near-term.
Dr. Anzalone's interview can be accessed on the Company's website at: www.arrowheadresearch.com.
Published on June 14, 2011, this edition of interviews by The Wall Street Transcript offers a timely review of the sector containing expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue may be obtained by calling (212) 952-7433 or via The Wall Street Transcript Online.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will be able to maintain our listing on any NASDAQ market, that our financial initiatives will succeed or that we will be able to continue to operate as a going concern. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.
To be added to the Company's email list to receive news directly, please send an email to
For more information, please click here
Investor Relations Contact:
The Piacente Group, Inc.
Copyright © Arrowhead Research CorporationIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
National Conference on Nanomaterials, (NCN-2017) April 21st, 2017
Nanomechanics, Inc. Unveils New Product at ICMCTF Show April 25th: Nanoindentation experts will launch the new Gemini that measures the interaction of two objects that are sliding across each other – not merely making contact April 21st, 2017
Nanotubes that build themselves April 14th, 2017
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers
Wood filter removes toxic dye from water April 21st, 2017
Better living through pressure: Functional nanomaterials made easy April 19th, 2017